Concepedia

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL <sup>pro</sup> Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Maren de Vries, Adil Mohamed, Rachel A. Prescott, Ana M. Valero-Jimenez, Ludovic Desvignes, Rebecca E. O’Connor, Claire M. Steppan, Joseph C. Devlin, Ellie Ivanova, Alberto Herrera,

Journal of Virology · 2021 · 142 citations · 56 references

DOIFull text

Open access

Concepts

Abstract

The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy.

References

56

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu, Dingyu Zhang, Xingwang Li et al. · New England Journal of Medicine · 2020 · 30.4K citations · Full text

, , +11

Comprehensive Integration of Single-Cell Data

Tim Stuart, Andrew Butler, Paul Hoffman et al. · Cell · 2019 · 16.9K citations · Full text

, , +14

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Alexander E. Gorbalenya, Susan C. Baker, Ralph S. Baric et al. · Nature Microbiology · 2020 · 7.7K citations · Full text

, , +14

Virological assessment of hospitalized patients with COVID-2019

Roman Wölfel, Victor M. Corman, Wolfgang Guggemos et al. · Nature · 2020 · 7.2K citations · Full text

, , +11

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Bin Cao, Yeming Wang, Danning Wen et al. · New England Journal of Medicine · 2020 · 5.5K citations · Full text

, , +15